[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session .

198 Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies in Complete Remission (BMB-CR) of Multiple Myeloma (MM) Patients Treated On Total Therapy  Protocols – Normalization of GEP Signature in Comparison with Normal Donor BMB (BMB-NL) and Consequences for Progression-Free Survival (PFS)

Program: Oral and Poster Abstracts
Type: Oral
Session: 651. Myeloma - Biology and Pathophysiology, excluding Therapy: Genomic and Molecular Determinant of Outcome in Myeloma
Sunday, December 9, 2012: 5:45 PM
Thomas Murphy Ballroom 1, Level 5, Building B (Georgia World Congress Center)

Christoph Heuck, MD1, Pingping Qu, PhD2*, Sarah Waheed, MD1, Saad Z Usmani, MD FACP1, Frits van Rhee, MD, PhD1, Madhav V. Dhodapkar, MD3, Joshua Epstein, DSc1, Qing Zhang, PhD1, Donald Johann, MD, MS1* and Bart Barlogie, MD, PhD1

1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
2Research and Biostatistics, Cancer Research and Biostatistics, Seattle, WA
3Department of Medicine / Hematology Section, Yale University School of Medicine, New Haven, CT

GEP of purified plasma cells (PC) provides superb risk discrimination for PFS and overall survival (OS). It is well established that MM engages the BM micro-environment (ME) and subjugates it toward its survival and progression. International Myeloma Working Group- and flow-based CR have been linked to PFS and OS, but do not provide guidance vis-à-vis the duration of post-transplant consolidation and maintenance therapy. We reasoned that ME may still be altered in flow-CR as it may remain MM-impregnated long after CR is established; conversely, ME normalization may happen much earlier. In a first step, 20 BMB-NL were compared with 331 untreated patients with MM (BMB-MM), leading to the discovery of a 65 gene score (GEP-65), which was then applied to 83 patients with MGUS/asymptomatic multiple myeloma (AMM) and 88 MM patients in CR. GEP-65 risk scores were similar in BMB-CR and BMB-MGUS-AMM contrasting with significantly lower values for BMB-MM.  Next we examined PFS for CR patients according to whether BMB-CR signature normalized (BMB-CR-NL, n=14) or failed to normalize (BMB-CR-MM, n=74). A borderline significantly superior PFS was observed in the former group suffering 2 events versus 31 in the remainder (p=0.08). We conclude that (1) BMB-MM differs markedly from BMB-NL, (2) BMB-CR resembles BMB-MGUS-AMM, and (3) BMB-CR-NL can be distinguished from BMB-CR-MM resulting in PFS differences. Availability of several hundred BMB-CR samples and nearly 100 BMB-NL will have been evaluated at the time of the meeting to address the following: (a) can these results be validated, (b) what is the time course of BMB-CR-NL and pattern to BMB-CR-MM and BMB-MM, (c) are there MM GEP molecular subgroup- and risk-dependent differences.

Description: Figure for heuck abstract.jpg

Disclosures: Dhodapkar: Celgene: Research Funding; KHK: Research Funding.

<< Previous Abstract | Next Abstract

*signifies non-member of ASH